FR-901228 Fujisawa/National Cancer Institute.
The depsipeptide FR-901228 is a histone deacetylas inhibitor under development by Fujisawa and the National Cancer Institute as a potential treatment for neoplasm. By May 2002, phase II trials had commenced in the US [452248], [461017].
Vigushin
David M
DM
Department of Cancer Medicine, MRC Cyclotron Building, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK. d.vigushin@ic.ac.uk
D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D047630:Depsipeptides; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000379:methods*; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D010456:Peptides, Cyclic / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D014481:United States
D047630:Depsipeptides; D056572:Histone Deacetylase Inhibitors; D010456:Peptides, Cyclic; C087123:romidepsin; D006655:Histone Deacetylases